1 September 2024

Starpharma to present at US Drug Delivery Conference

Melbourne, Australia; Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it will be presenting its DEP™ platform at the 4th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston this week.

 

PODD is attended by around 250 senior licensing and development executives from pharma and biotech with an interest in Drug Delivery.  Speakers include industry experts from Roche, Amgen, Biogen Idec, Astra Zeneca, Boehringer Ingelheim, Janssen, Merck Serono, Novartis, Novo Nordisk Sanofi and Teva.

 

Starpharma’s presentation provides an overview of Starpharma’s DEP™ platform with a particular focus on the company’s recent work in targeted DEP™ conjugates including those which target the same HER-2 receptors as the highly successful cancer drug Herceptin.

 

View Presentation: Starpharma to present at US Drug Delivery Conference ( pdf file, 807kb)

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.